Physician profile
Haroon Ilyas
NPI 1477521052
$109,115.01
in general payments reported to CMS, 2019-2025
37 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $4,706 · 2021: $12K · 2022: $4,996 · 2023: $9,460 · 2024: $21K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $36K · Food and Beverage: $13K · Travel and Lodging: $3,737 · Consulting Fee: $1,725 · Education: $27.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,800.00 |
| Food and Beverage | $13,340.79 |
| Travel and Lodging | $3,737.13 |
| Consulting Fee | $1,725.00 |
| Education | $27.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $45,088.56 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20,657.25 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $15,687.22 | 2019-2025 | Cequa |
| Ocular Therapeutix, INC. | $4,033.65 | 2019-2025 | Dextenza |
| Abbvie INC. | $3,155.66 | 2022-2025 | |
| Alcon Vision LLC | $2,341.31 | 2019-2025 | Constellation, Unity, Hydrus Microstent |
| Allergan, INC. | $2,117.98 | 2019-2022 | |
| Harrow Eye, LLC | $1,966.25 | 2023-2025 | Iheezo, Triesence, Vevye |
| Kala Pharmaceuticals, INC. | $1,796.22 | 2019-2022 | |
| Horizon Therapeutics Plc | $1,573.42 | 2019-2023 | Tepezza |
| New World Medical,INC. | $1,505.06 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $1,427.08 | 2019-2020 | |
| Eyepoint US, INC. | $1,347.05 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $838.75 | 2021-2025 | Tecnis Iol |
| Glaukos Corporation | $818.62 | 2020-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr, Idose |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $554.31 | 2020-2025 | Acthar |
| Oyster Point Pharma, INC. | $553.85 | 2022-2024 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $523.47 | 2023-2025 | Purified Cortrophin Gel, Iluvien |
| Tarsus Pharmaceuticals, INC. | $473.87 | 2024-2025 | Xdemvy |
| Ivantis, INC | $445.36 | 2019-2021 | |
| Dompe US, INC. | $282.68 | 2021-2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $266.72 | 2019-2023 | |
| Sight Sciences, INC. | $240.32 | 2019-2022 | |
| Rxsight INC | $237.01 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Amgen INC. | $196.53 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $185.80 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $162.57 | 2019 | |
| Shire North American Group INC | $138.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Biotissue Holdings INC. | $116.75 | 2022-2025 | |
| Lensar, INC. | $87.16 | 2020-2025 | Lensar Laser System |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Thea Pharma INC. | $27.25 | 2022 | |
| Astellas Pharma US INC | $25.59 | 2023 | |
| Akorn Operating Company LLC | $25.36 | 2021 | |
| Apellis Pharmaceuticals, INC. | $14.46 | 2025 | Syfovre |
| Beaver-Visitec International, INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haroon Ilyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.